Barclays PLC Buys 133,653 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Barclays PLC boosted its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 362.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 170,546 shares of the medical technology company’s stock after buying an additional 133,653 shares during the quarter. Barclays PLC’s holdings in Alphatec were worth $948,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in ATEC. XTX Topco Ltd purchased a new stake in Alphatec during the third quarter valued at about $69,000. Net Worth Advisory Group purchased a new stake in Alphatec during the third quarter valued at about $76,000. Van ECK Associates Corp lifted its holdings in Alphatec by 57.0% during the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock valued at $99,000 after purchasing an additional 6,998 shares during the last quarter. Tempus Wealth Planning LLC purchased a new stake in Alphatec during the third quarter valued at about $107,000. Finally, Atria Investments Inc lifted its holdings in Alphatec by 8.0% during the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after purchasing an additional 1,460 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Alphatec Stock Down 1.2 %

Shares of NASDAQ ATEC opened at $9.08 on Tuesday. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $17.34. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The firm’s 50 day simple moving average is $8.81 and its two-hundred day simple moving average is $8.05. The stock has a market capitalization of $1.29 billion, a P/E ratio of -7.09 and a beta of 1.38.

Analyst Upgrades and Downgrades

ATEC has been the topic of several recent research reports. Barclays upped their price objective on shares of Alphatec from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Thursday, October 31st. Needham & Company LLC reissued a “buy” rating and issued a $13.00 price target on shares of Alphatec in a report on Thursday, October 31st. Finally, Lake Street Capital lowered their price target on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Alphatec presently has an average rating of “Moderate Buy” and an average price target of $17.11.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.